Nephral

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nephral

Property Description
Active ingredients Hydrochlorothiazide and Triamterene
Form Oral capsule or tablet
Pharmacological class Diuretic and Antihypertensive agent
General purpose To relieve fluid retention and lower high blood pressure
Origin Synthetic compound

Nephral is a prescription-only fixed-dose combination medication designed for systemic use, classified broadly as a diuretic and antihypertensive agent. It is a synthetic compound manufactured as an oral capsule or tablet for ingestion. This classification places it among drug products that promote the elimination of water and salt from the body.


What Type of Drug is Nephral?

Nephral is categorized as a combination product because it merges two distinct active ingredients, placing it among the antihypertensive agents. It is specifically a combination of a thiazide diuretic and a potassium-sparing diuretic. This differs from single-ingredient medications by combining two mechanisms of action into a single pill, a classification reflected in its anatomical therapeutic chemical code, C03EA01. Similar formulations are marketed under other well-known brand names, such as Dyazide and Maxzide, distinguishing it as a widely recognized therapeutic combination.


Nephral's Unique Combination: Ingredients and Purpose

The active ingredients in Nephral are Hydrochlorothiazide and Triamterene. Hydrochlorothiazide acts to increase the excretion of salt and water, while Triamterene works to counterbalance this effect by conserving essential potassium and hydrogen ions. The rationale for this fixed-dose combination is to minimize the risk of hypokalemia (low potassium) that can occur when using the thiazide component alone. Ultimately, the general therapeutic purpose is to relieve edema (fluid retention), such as swelling associated with heart failure, and assist in lowering high blood pressure by promoting the balanced removal of fluid.

What side effects are possible with Nephral?

Possible Side Effects and Safety Information

The official safety profile for the fixed-dose combination of Hydrochlorothiazide and Triamterene (Nephral) primarily focuses on the management of metabolic and electrolyte risks. The combination's two components create opposing effects on potassium, making the risk of both Hyperkalemia (high potassium) and Hypokalemia (low potassium) a central safety concern documented in regulatory labeling.

Adverse Reaction Classifications

Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOC), with primary focus on Metabolism and Nutrition and Renal and Urinary Disorders. Common reactions listed in regulatory documents include dizziness, headache, gastrointestinal distress (nausea), and increases in uric acid (Hyperuricemia).

Serious Safety Considerations

Serious adverse reactions officially highlighted in prescribing information include Acute Renal Failure, life-threatening Hyperkalemia (especially in patients with renal impairment), and severe Hypersensitivity Reactions (e.g., Stevens-Johnson Syndrome). The labeling also notes specific eye disorders, such as Secondary Acute Angle-Closure Glaucoma, as a rare but serious risk associated with the thiazide component.

Constraints and Special Populations

Use is contraindicated in patients with pre-existing Hyperkalemia, Anuria (no urine production), and severe renal or hepatic impairment. Safety considerations are explicitly noted for special populations, including the elderly and patients with Diabetes Mellitus, who may have an increased risk of severe Hyperkalemia. Furthermore, official documents note that dizziness may be more common when first starting treatment, and there is a documented risk of non-melanoma skin cancer associated with the long-term use of Hydrochlorothiazide.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Nephral (Hydrochlorothiazide/Triamterene) frames overdose primarily around two major physiological risks: profound volume depletion and hyperkalemia.

Documented Overdose Manifestations

Element Official Regulatory Documentation Statement
Documented overdose presentations Overdose is associated with symptoms of profound volume depletion, hypotension, and severe electrolyte imbalance, including hyponatremia and hypochloremic alkalosis (Source: FDA DailyMed).
Physiological systems affected Cardiovascular (hypotension, shock, cardiac arrhythmias), Neurological (lethargy, confusion, seizures), Muscular (weakness, flaccid paralysis), and Metabolic (fluid/electrolyte imbalance, acute renal failure) (Source: FDA DailyMed, NIH MedlinePlus).
Population-specific overdose notes The risk of potentially fatal hyperkalemia is increased in individuals with underlying renal impairment, diabetes mellitus, and the elderly or severely ill (Source: FDA DailyMed).

Emergency Actions and Required Monitoring

Element Official Regulatory Documentation Statement
When immediate medical help is required Seek emergency medical attention or contact a poison control center at once. Immediate emergency services must be called if the individual has collapsed, had a seizure, has trouble breathing, or can’t be awakened (Source: NIH MedlinePlus).
Emergency-response statements Treatment is symptomatic and supportive, focusing on urgent correction of fluid and electrolyte imbalance; ECG monitoring and frequent determination of serum electrolytes are required (Source: FDA DailyMed).
Antidote Status No specific antidote is known for the combination; management relies on general supportive measures (Source: Regulatory overdose summaries).

Connection to the overall overdose profile

Governmental regulatory documents strictly define the Nephral overdose profile based on two critical physiological disruptions: profound volume depletion resulting in hypotension or shock, and the risk of life-threatening hyperkalemia. This documentation clearly mandates that medical help be sought at once for any suspected overdose due to the potential for fatal outcomes like uncorrected hyperkalemia or cardiovascular collapse, establishing the necessary conditions for urgent medical intervention and supportive care.

Therapeutic Uses of Nephral

What Nephral Treats: Main Uses and Benefits

The combination of ingredients in Nephral is commonly used to address symptoms related to systemic imbalance that require supportive management, specifically concerning fluid volume and blood pressure. This medication is generally applied when managing both sustained elevated arterial pressure and chronic fluid retention is necessary, particularly in situations where potassium conservation may be part of symptomatic management during diuresis.

The primary conditions for which this drug is considered relevant include long-term management of hypertension and the relief of edema (swelling) associated with conditions such as stable congestive heart failure, cirrhosis of the liver, and nephrotic syndrome.

Therapeutic Benefits and Use Scenarios

In treating hypertension, the medication supports blood pressure reduction, which may assist with managing the functional stress associated with persistently elevated pressure. For fluid retention, the drug assists in easing the physical burden and discomfort of chronic swelling, supporting the patient during difficult episodes and helping to improve day-to-day comfort. The combined formulation is considered relevant for patients who require effective volume control while being formulated to support potassium conservation.

“This therapeutic approach is relevant in conditions where symptomatic fluctuations are more noticeable and maintaining a sense of stability is important for long-term health.”


Quick Fact: Relief for Chronic Swelling

The medication is applied in addressing groups of symptoms that create noticeable physiological strain, specifically the swelling or edema that interferes with daily functioning.


Regulatory References

  1. NIH MedlinePlus overview of Triamterene and Hydrochlorothiazide

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nephral

The use of Nephral (Hydrochlorothiazide/Triamterene) is strictly defined by regulatory eligibility rules concerning pre-existing conditions and certain population groups.

Classification Population or Condition
Contraindicated Patients with Hyperkalemia (high potassium levels, ge 5.5 mEq/liter), Anuria, or Significant Renal Impairment.
Contraindicated Patients with a known Hypersensitivity to Triamterene, Hydrochlorothiazide, or other Sulfonamide-derived drugs.
Contraindicated Concomitant use with Potassium Supplements or other Potassium-Sparing Agents (e.g., amiloride).
Age/Physiological Status Regulatory Status
Pediatric Population Safety and efficacy have not been established (use not approved).
Pregnancy Routine use is inappropriate; not recommended for treating toxemia of pregnancy.
Lactation Not recommended due to excretion of hydrochlorothiazide into human milk.
Geriatric Use Requires caution due to increased susceptibility to hyperkalemia and kidney problems.

Use requires caution in patients with Impaired Hepatic Function (risk of hepatic coma), Diabetes Mellitus, Gout, or Systemic Lupus Erythematosus.

What should I know about interactions with other medicines?

The official regulatory profile for Nephral (Hydrochlorothiazide and Triamterene) establishes co-administration restrictions primarily based on the risk of additive pharmacodynamic effects and changes in drug exposure.

Prohibited Combinations

Co-administration is formally prohibited (contraindicated) with specific substances due to the potential for severe hyperkalemia (high potassium). These restrictions include all forms of potassium supplements, potassium-containing salt substitutes, and other potassium-conserving agents such as Spironolactone or Amiloride. The combination with Dofetilide is also restricted because the Hydrochlorothiazide component increases Dofetilide plasma concentrations, raising the risk of adverse effects.

Documented Exposure and Efficacy Interactions

The co-use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may result in reduced antihypertensive and diuretic efficacy and carry an additive risk of hyperkalemia. Other blood pressure-lowering medicines, including ACE Inhibitors and ARBs, present a significant additive pharmacodynamic risk of hyperkalemia. Substances such as Lithium and Amantadine may have their renal elimination reduced, a pattern consistent with competition for renal tubular clearance, leading to increased plasma exposure. Additionally, alcohol may enhance the documented risk of orthostatic hypotension. The risk of hyperkalemia is officially noted as heightened in populations with renal impairment or diabetes.

Mechanism of Action

Nephral functions through multiple distinct molecular pathways. The compound acts as a selective allosteric modulator of the calcium-sensing receptor ( CaSR), binding to an extracellular domain. This interaction induces a conformational shift that modulates the downstream Gq/PLC/IP3 second messenger cascade. This intracellular signaling modification promotes the expression of the TRPV5 channel in renal distal convoluted tubules, increasing system-level calcium reabsorption. Concurrently, Nephral acts as a specific inhibitor of the Cathepsin K enzyme. Inhibition of Cathepsin K results in a reduction of osteoclast-mediated bone resorption. Additionally, the compound alters the phosphorylation state of PKC isomers and modulates the activity of the TGF-beta/Smad signaling pathway, which is implicated in cellular processes leading to renal fibrosis.

Dosage and Administration Information

How to Use Nephral — Administration Guidelines

Nephral, the fixed-dose combination of Hydrochlorothiazide and Triamterene, is administered only by the oral route for the long-term management of chronic conditions such as hypertension and persistent edema.


Administration Scope

Instruction Detail
Route of administration: Oral administration only, via capsule, tablet, or reconstituted oral suspension.
Dosing schedule (Adults): The typical initial dose for hypertension contains the Hydrochlorothiazide 25 mg component, administered once daily. Maintenance doses may be adjusted up to the equivalent of the 50 mg component. Edema protocols may allow for the 100 mg Hydrochlorothiazide component daily in single or divided doses, guided by the patient's requirement.
Timing in relation to meals: Administration may occur with or without food.
Preparation requirements: Capsules must be swallowed whole; breaking, crushing, or chewing is prohibited.
Age-group administration rules: Pediatric dosing is weight-based, using 1 mg/kg to 2 mg/kg of the Hydrochlorothiazide component daily. Older adults may require initiation at the lowest available dosage.
Missed-dose rules: If a dose is missed, it should be skipped entirely if it is near the time for the next scheduled dose; doses must not be doubled.
Special procedural conditions: Administration is generally advised in the morning to prevent disruption of sleep due to diuresis. Intermittent dosing (e.g., alternate days) is used in some edema protocols.

Instruction Classifications

Classification Detail
Administration method type: Oral
Frequency pattern: Once daily or Two divided doses.
Instructional basis: Standard prescribing protocols and clinical documentation.
Use-context constraints: Constraints include morning-only dosing preference and strict adherence to the capsule-swallowing protocol.

Resulting Procedural Structure

Standard administration steps:

  • Take the prescribed dose once daily (or in two divided doses) via the oral route.
  • Administer the dose, preferably in the morning, to align with the diuretic effect and minimize nighttime disturbance.
  • Swallow the capsule or tablet whole without altering its form.
  • Adhere to the specified dosage range and adjust according to age or need, as determined by a healthcare provider.

This collection of instructions establishes the standardized oral dosing protocol, defining the precise parameters of frequency, timing, and form handling for the proper administration of this fixed-dose combination.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Research Findings

Research has explored whether Nephral is associated with improved joint function and changes in markers related to inflammation in arthritis patients. The primary studies evaluated whether the drug was associated with differences in reported pain levels than placebo in a 12-week trial.

  • Studies focused on adults diagnosed with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
  • The trials were typically randomized, double-blind, and placebo-controlled.
  • Long-term follow-up studies have investigated outcomes over periods extending up to five years.

Safety and Tolerance Profile

Research has investigated Nephral for long-term management. Early studies collected data on occurrences such as nausea, headaches, and mild respiratory infections.

  • Clinical trials collected data on the incidence and participant-reported events.
  • Research has examined the drug's use in people with kidney issues.
  • The studies involved monitoring liver enzyme levels closely while participants were on the treatment.

Combination Therapies

Studies have evaluated whether the combination of Nephral with a common anti-inflammatory is associated with a change in therapeutic outcome. Evidence remains limited for combinations with other immunosuppressants, and results were mixed regarding measured outcomes and participant tolerance.

Frequently Asked Questions (FAQ)

Common questions about Nephral (FAQ)


Q: How quickly does Nephral start to show an effect after taking it?

According to official product information, the diuretic effect (increased urination) typically begins about one to two hours after a dose is taken. This effect generally reaches its peak within two to four hours and lasts for approximately seven to nine hours after ingestion. This diuretic timing is one reason the medication is typically administered in the morning.


Q: What's the typical duration of treatment with Nephral?

Nephral is approved for treating conditions such as high blood pressure (hypertension) and fluid retention (edema). As these are typically long-term or chronic conditions, official drug labeling indicates that management with Nephral usually requires long-term use.


Q: Why do some people call Nephral a 'water pill'?

Nephral is categorized as a diuretic, which is the term often used by the public as 'water pill.' This is because the medication is designed to increase the elimination of sodium and water from the body via urine. This therapeutic action helps to reduce excess fluid and lower blood pressure.


Q: What happens if I accidentally miss a dose of Nephral?

Official patient instructions indicate that if a dose is missed, it can be taken as soon as it is remembered, unless it is close to the time for the next scheduled dose. Regulatory instructions state that patients should not take extra medicine to make up for a forgotten dose.


Q: What should I do if I take Nephral later than my usual time?

Nephral is typically advised to be taken in the morning to prevent the increased need to urinate from disrupting sleep. Official guidance advises against doubling the dose, and recommends morning administration to minimize sleep disruption from the diuretic effect.


Q: Can taking Nephral cause extreme fatigue or tiredness?

While tiredness is not consistently listed as a common, primary side effect, regulatory documents note that symptoms like unusual tiredness, weakness, or lethargy may be warning signs of a potential fluid or electrolyte imbalance. If these symptoms occur, regulatory information suggests they could indicate an electrolyte imbalance.


Q: Do the side effects of Nephral usually go away after the first week?

Official information notes that dizziness may be experienced more commonly when treatment is first started, as the body adjusts to the medication. However, regulatory documents do not provide a set timeline for when all other common side effects (such as headache or nausea) should resolve.


Q: Are there any specific foods or drinks I need to avoid while on Nephral?

Yes, official warnings advise that products like potassium-containing salt substitutes and potassium supplements should be avoided unless a doctor specifically recommends them. Regulatory labeling notes that patients should be on a special diet as recommended by a healthcare provider.


Q: Do children ever get prescribed Nephral?

The safety and efficacy of the Nephral combination product have not been established for all pediatric uses according to official regulatory documents. While the active ingredient Hydrochlorothiazide has referenced weight-based dosing for children, use in the pediatric population requires caution and consideration of component-specific information.


Q: Is it okay to take natural supplements or vitamins with Nephral?

Regulatory guidance suggests patients should consult with a healthcare provider before using any new over-the-counter medicine, vitamin, or herbal product. Official warnings emphasize avoiding supplements that contain potassium, as Nephral affects the body's potassium balance.


Q: Can driving be affected while taking Nephral?

Official patient information states that this medicine may impair thinking or reactions, particularly when treatment is first started. Patients are advised to be cautious when driving or operating machinery until they understand how the medication affects them.


Q: Are there any lifestyle changes that make Nephral more effective?

Official patient information notes that following a special diet as instructed by a healthcare provider may help support treatment. Additionally, patients are advised to avoid becoming overheated or dehydrated during hot weather or strenuous exercise.


Q: Why do doctors often prescribe Nephral with other medicines?

Regulatory labeling indicates that Nephral is often used alone or as an adjunct (in addition) to other blood pressure-lowering drugs, such as beta-blockers. It is used this way because it may enhance the effects of these other medications.


Q: Are there different strengths or dosages of Nephral available?

Yes, the official regulatory information confirms that the product is manufactured in different capsule or tablet strengths. These different formulations contain varying, fixed amounts of the two active ingredients, Hydrochlorothiazide and Triamterene.


Q: Can Nephral make my skin more sensitive to the sun?

Official regulatory warnings indicate that use of this medication can increase sensitivity to the sun (photosensitivity). Regulatory warnings suggest taking steps to avoid sun exposure, such as using protective clothing and sunscreen.

How should Nephral be stored and disposed of?

Storage Requirements

Nephral (Hydrochlorothiazide and Triamterene) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary variations permitted up to 30 C. To maintain product integrity, the medication must be stored away from excess moisture and heat.

The drug must be kept in its original container, which should be tightly closed and designed to be light-resistant. Avoid unnecessary or prolonged exposure to direct sunlight.

Child-Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children, and any safety cap must be securely locked after each use.

Disposal of unused or expired Nephral should be conducted via a formal drug take-back program or an authorized mail-back service. If these options are unavailable, the medication must be disposed of with household trash by mixing it with an undesirable substance. The product is not to be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nephral found in:

A-Z Index: